The Maintenance Effect of Enstilar Foam in Combination With Otezla

Part of paid clinical trials in Louisville, Kentucky.

Sponsor
Derm Research, PLLC
Study ID
NCT04555707
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apremilast 30mg — DRUG
    30mg PO BID started within 10 days of baseline
  • calcipotriene and betamethasone dipropionate — DRUG
    1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.

Study Details

This is a single-center, open-label study. Approximately 30 qualified subjects will be enrolled in a study lasting 20 weeks which investigates the effect of Enstilar used in combination with Otezla to treat psoriasis.

Key Dates

First listed
Sep 21, 2020
Start date
Jun 24, 2020
Status verified
Oct 2020
Primary completion
Jun 30, 2021
Completion
Sep 30, 2021

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Otezla + Enstilar

Primary Outcome Measure

Percent of subjects who are clear or almost clear on Physicians Global Assessment at Week 4 [ Time Frame: 4 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Skin Sciences, PLLCLouisvilleKentucky40217
Senen Pena Oliva, MSN
[email protected]
502-451-9000

Find similar trials in Louisville, KY

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Skin Sciences, PLLC· Louisville, KY

Related Studies